BUZZ - Lamb Weston shares rise after raising its annual performance outlook
路透社2026/10/06 14:12Latest Update October 6 - Lamb Weston (LW.N) shares surged as much as 9.5% to $48.81—if the gain holds, this would be the company's best single-day performance since July 2025. The frozen French fries supplier raised its annual revenue growth forecast from a previous estimate of flat to 1% to a low single-digit growth rate, expecting demand to remain resilient, especially in its largest revenue-contributing region, North America. The company also raised its adjusted earnings per share forecast for fiscal 2027 from a range of $2.95-$3.25 to $3.05-$3.35. First-quarter North America sales grew 5%. Actual results exceeded market expectations for both first-quarter sales and adjusted profit. As of the previous trading day’s close, the stock is up 6.4% year to date. (For the convenience of non-English speakers, Reuters provides its reports in several other languages using automated translation. Due to potential errors or lack of accurate context in automated translations, Reuters does not guarantee their accuracy. Automated translations are offered solely for reader convenience. Reuters is not liable for any harm or loss resulting from the use of automated translation.)
Latest Developments
October 6 - ** Lamb Weston LW.N shares surged as much as 9.5% to $48.81—if the gains hold, this would mark the company's best single-day performance since July 2025
** The frozen french fries supplier has raised its annual revenue growth outlook from flat to 1% previously estimated, up to a low single-digit growth rate (link)
** Demand is expected to remain resilient, especially in North America, which contributes the largest revenue
** Fiscal 2027 adjusted earnings per share guidance raised from $2.95–$3.25 to $3.05–$3.35
** First-quarter North America sales rose 5%
** Actual results outperformed market expectations for first-quarter sales and adjusted profit
** As of the previous session close, shares are up 6.4% year-to-date
(To assist non-English speakers, Reuters provides automated translations of its reports in several other languages. As automated translation may be inaccurate or lack necessary context, Reuters does not guarantee the accuracy of the translated text and provides it solely for the convenience of readers. Reuters accepts no responsibility for any damage or loss caused by the use of automated translation.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Kraft Heinz General Counsel Angel S. Willis resigns effective Oct. 20
Kraft Heinz EVP, Global General Counsel and Corporate Affairs Officer Angel S. Willis will resign effective Oct. 20, 2026. Willis notified the company on Oct. 2, 2026, citing plans to pursue other opportunities. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. The Kraft Heinz Company published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001637459-26-000067), on October 06, 2026, and is solely responsible for the information contained therein.
BUZZ-Fair Isaac shares fall as implementation of AI plan leads to 15% layoffs
On October 6, the shares of credit scoring giant Fair Isaac (FICO.N) fell 2.4% in after-hours trading, closing at $679.01. The company announced it would cut approximately 15% of its workforce to streamline management, simplify operations, and integrate AI-driven product development. Affected employees started receiving notifications during the week of October 5. The company expects the restructuring plan to be substantially complete by the third quarter of fiscal year 2027. Fair Isaac anticipates a pre-tax charge of around $27 million in the fourth quarter of fiscal year 2026, mainly related to severance packages and employee costs, with most of these expenses expected to result in future cash outflows. By the close of the previous trading day, Fair Isaac’s share price had declined by about 59% year to date. (For the convenience of non-English speakers, Reuters has automated the translation of its reports into several other languages. As automated translation may contain errors or lack necessary context, Reuters does not guarantee the accuracy of the automated translation, which is provided solely for readers’ convenience. Reuters is not liable for any damages or losses resulting from the use of the automated translation function.)
IB Acquisition flags Nasdaq noncompliance after missing annual shareholder meeting deadline
Nasdaq notified IB Acquisition on Oct. 5, 2026 it is out of compliance with Listing Rule 5620(a) for missing its annual meeting deadline. Company has 45 days to submit a compliance plan; Nasdaq can grant an exception through March 29, 2027. Letter does not immediately affect the Nasdaq Capital Market listing; shares continue trading under IBAC during the compliance period. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IB Acquisition Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-045994), on October 06, 2026, and is solely responsible for the information contained therein.
BUZZ - Caribou shares fall after discontinuing cell therapy program and launching strategic review
On October 6th, shares of biotech company Caribou Biosciences (CRBU.O) fell by 36.1% in after-hours trading to $0.73. The company announced it is exploring potential sale, merger, or other options to unlock shareholder value. Caribou plans to discontinue the development of its experimental cell therapy vispa-cel for a certain blood cancer, as well as CB-011 for treating the bone marrow cancer—multiple myeloma. The company stated that vispa-cel is ready for clinical trials, and it has reached an agreement with the FDA on the design for late-stage clinical trials. However, the difficult financing environment for allogeneic CAR-T therapies has made it challenging to raise the necessary funds to advance these projects. Caribou also intends to lay off employees and cut costs; according to its report, as of June 30, 2026, the company held $113.8 million in cash, cash equivalents, and marketable securities. As of the previous trading day’s close, the stock had fallen about 29% year-to-date. (For the convenience of non-English speakers, Reuters provides automated translation of its reports into several languages. As automated translations may contain errors or lack context, Reuters does not guarantee the accuracy of automated translation texts and provides them solely for reader convenience. Reuters assumes no liability for any harm or loss from use of the automated translation feature.)
Crypto prices
More
